These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 27923197)

  • 1. Single chain Fc-dimer-human growth hormone fusion protein for improved drug delivery.
    Zhou L; Wang HY; Tong S; Okamoto CT; Shen WC; Zaro JL
    Biomaterials; 2017 Feb; 117():24-31. PubMed ID: 27923197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics.
    Dumont JA; Low SC; Peters RT; Bitonti AJ
    BioDrugs; 2006; 20(3):151-60. PubMed ID: 16724863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
    Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
    J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral and pulmonary delivery of FSH-Fc fusion proteins via neonatal Fc receptor-mediated transcytosis.
    Low SC; Nunes SL; Bitonti AJ; Dumont JA
    Hum Reprod; 2005 Jul; 20(7):1805-13. PubMed ID: 15817590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of protein aggregates on characterization of FcRn binding of Fc-fusion therapeutics.
    Bajardi-Taccioli A; Blum A; Xu C; Sosic Z; Bergelson S; Feschenko M
    Mol Immunol; 2015 Oct; 67(2 Pt B):616-24. PubMed ID: 26254986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and characterization of human growth hormone-Fc fusion proteins for transcytosis induction.
    Lee CH; Woo JH; Cho KK; Kang SH; Kang SK; Choi YJ
    Biotechnol Appl Biochem; 2007 Apr; 46(Pt 4):211-7. PubMed ID: 17067288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monomeric IgG1 Fc molecules displaying unique Fc receptor interactions that are exploitable to treat inflammation-mediated diseases.
    Ying T; Feng Y; Wang Y; Chen W; Dimitrov DS
    MAbs; 2014; 6(5):1201-10. PubMed ID: 25517305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fc-Fusion Drugs Have FcγR/C1q Binding and Signaling Properties That May Affect Their Immunogenicity.
    Lagassé HAD; Hengel H; Golding B; Sauna ZE
    AAPS J; 2019 May; 21(4):62. PubMed ID: 31062128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fc engineering: serum half-life modulation through FcRn binding.
    Olafsen T
    Methods Mol Biol; 2012; 907():537-56. PubMed ID: 22907373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells.
    Goebl NA; Babbey CM; Datta-Mannan A; Witcher DR; Wroblewski VJ; Dunn KW
    Mol Biol Cell; 2008 Dec; 19(12):5490-505. PubMed ID: 18843053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of divalent H-2Kd/IgG2aFc fusion protein to murine macrophage via Fc-FcR interaction.
    Xiao W; Chen X; Lin Zhou ; Lu S; Liang Z; Wu X
    Cell Mol Immunol; 2007 Apr; 4(2):147-51. PubMed ID: 17571461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein.
    Seijsing J; Lindborg M; Höidén-Guthenberg I; Bönisch H; Guneriusson E; Frejd FY; Abrahmsén L; Ekblad C; Löfblom J; Uhlén M; Gräslund T
    Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17110-5. PubMed ID: 25406323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of Peptide-Fc fusion proteins.
    Wu B; Sun YN
    J Pharm Sci; 2014 Jan; 103(1):53-64. PubMed ID: 24285510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Half-life extended biotherapeutics.
    Kontermann RE
    Expert Opin Biol Ther; 2016 Jul; 16(7):903-15. PubMed ID: 26967759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance.
    Shan L; Dyk NV; Haskins N; Cook KM; Rosenthal KL; Mazor R; Dragulin-Otto S; Jiang Y; Wu H; Dall'Acqua WF; Borrok MJ; Damschroder MM; Oganesyan V
    Commun Biol; 2021 Sep; 4(1):1048. PubMed ID: 34497355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
    Wang Y; Tian Z; Thirumalai D; Zhang X
    J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway.
    Dumont JA; Bitonti AJ; Clark D; Evans S; Pickford M; Newman SP
    J Aerosol Med; 2005; 18(3):294-303. PubMed ID: 16181004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics.
    Mathur A; Arora T; Liu L; Crouse-Zeineddini J; Mukku V
    J Immunol Methods; 2013 Apr; 390(1-2):81-91. PubMed ID: 23384837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering a monomeric Fc domain modality by N-glycosylation for the half-life extension of biotherapeutics.
    Ishino T; Wang M; Mosyak L; Tam A; Duan W; Svenson K; Joyce A; O'Hara DM; Lin L; Somers WS; Kriz R
    J Biol Chem; 2013 Jun; 288(23):16529-16537. PubMed ID: 23615911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, Pharmacodynamics, and Efficacy of a Novel Long-Acting Human Growth Hormone: Fc Fusion Protein.
    Kim SJ; Kwak HH; Cho SY; Sohn YB; Park SW; Huh R; Kim J; Ko AR; Jin DK
    Mol Pharm; 2015 Oct; 12(10):3759-65. PubMed ID: 26370910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.